Certolizumab pegol (Cimzia)

Certolizumab pegol is a biologic medication for the treatment of Crohn's disease, rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

It is a fragment of a monoclonal antibody specific to TNF-alpha to neutralise it.

It is administered through subcutaneous injection every month.

In 2016, it sold €120 million in Europe.

It has an immunogenicity rate of 3-37%.

Labs that test for drug level:

Wieslab
Sanquin
United Medix Labs

Labs that test for ADA titre:

Wieslab
Sanquin
United Medix Labs